Gland Pharma · NSE: GLAND · BSE: 543245
Q3 FY21 results · Oct–Dec 2020
Gland Pharma reported revenue from operations of ₹859.42 crore and net profit of ₹204.11 crore for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 859.42 | — | — | — | — |
| Other income | 35.13 | — | — | — | — |
| Total income | 894.55 | — | — | — | — |
| Profit before tax | 273.24 | — | — | — | — |
| Net profit for the period | 204.11 | — | — | — | — |
| EPS, basic (₹) | 12.83 | — | — | — | — |
| Net margin (%) | 23.7 | — | — |
Standalone
- Filed with BSE
- 22 Jan 2021, 17:55 IST
- Board meeting
- 22 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE